88 related articles for article (PubMed ID: 4039904)
1. Cisplatin and plasma iron levels.
Grau JJ; Estape J; Daniels M; Guzman MC; Santabarbara P
Ann Intern Med; 1985 Jul; 103(1):158-9. PubMed ID: 4039904
[No Abstract] [Full Text] [Related]
2. Dose and schedule effects of cisplatin on the related acute iron changes.
Pollera CF; Ameglio F; Nardi M; Marolla P; Carlini P; Frasca AM
Oncology; 1990; 47(2):133-8. PubMed ID: 2314826
[TBL] [Abstract][Full Text] [Related]
3. Effect of cisplatin on erythropoietin and iron changes.
Onat H; Inanc SE; Dalay N; Karaloglu D; Ertürk N; Yasasever V
Eur J Cancer; 1993; 29A(5):777. PubMed ID: 8471341
[No Abstract] [Full Text] [Related]
4. Elevated serum iron levels following administration of cisplatinum.
Kletter G; Parks BR; Bhatnagar A; Iyer RV
Oncology; 1988; 45(6):421-3. PubMed ID: 3186150
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced atrial fibrillation.
Menard O; Martinet Y; Lamy P
J Clin Oncol; 1991 Jan; 9(1):192-3. PubMed ID: 1985170
[No Abstract] [Full Text] [Related]
6. Effect of cisplatin on plasma renin activity and serum aldosterone levels.
Kurt E; Manavoglu O; Dilek K; Orhan B; Evrensel T
Clin Nephrol; 1999 Dec; 52(6):397-8. PubMed ID: 10604651
[No Abstract] [Full Text] [Related]
7. High-dose cisplatin for lung cancer.
Bhuchar VK; Lanzotti VJ
Cancer Treat Rep; 1982 Feb; 66(2):375-6. PubMed ID: 7198939
[No Abstract] [Full Text] [Related]
8. Non-protein bound iron release during chemotherapy in cancer patients.
Weijl NI; Elsendoorn TJ; Moison RM; Lentjes EG; Brand R; Berger HM; Osanto S
Clin Sci (Lond); 2004 May; 106(5):475-84. PubMed ID: 14670072
[TBL] [Abstract][Full Text] [Related]
9. Turning up the heat on nonsmall cell lung cancer: is the toxicity of concurrent cisplatin-based chemotherapy and accelerated fractionation acceptable?
Byhardt RW
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):431-3. PubMed ID: 7836100
[No Abstract] [Full Text] [Related]
10. [Effect of fosfomycin on cisplatin-induced renal tubular damage].
Itoh H; Watanabe A; Ooka T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):147-50. PubMed ID: 2297234
[No Abstract] [Full Text] [Related]
11. Cisplatin-induced anemia: a potential interference with iron metabolism at erythroid progenitors level.
Dufour P; Bergerat JP; Eber M; Renaud P; Karcher V; Giron C; Leroy MJ; Oberling F
Anticancer Drugs; 1990 Oct; 1(1):49-54. PubMed ID: 2131037
[TBL] [Abstract][Full Text] [Related]
12. [A case of second-degree atrioventricular block caused by high dose cisplatin treatment].
Tasaka T; Fujita J; Futami H; Yamaji Y; Hata Y; Bungo M; Nakamura H; Shiotani T; Irino S
Gan To Kagaku Ryoho; 1991 May; 18(6):1047-50. PubMed ID: 2029191
[TBL] [Abstract][Full Text] [Related]
13. Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
Kanat O; Evrensel T; Kurt E; Keskin K; Akcali U; Manavoglu O
Lung Cancer; 2007 Apr; 56(1):143-4. PubMed ID: 17291625
[TBL] [Abstract][Full Text] [Related]
14. [Changes in blood iron levels during cisplatin chemotherapy. Preliminary results].
Sartori S; Nielsen I; Malacarne P
Medicina (Firenze); 1990; 10(1):48-9. PubMed ID: 2381283
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients.
Demkow U; Stelmaszczyk-Emmel A
Respir Physiol Neurobiol; 2013 Jun; 187(1):64-7. PubMed ID: 23548823
[TBL] [Abstract][Full Text] [Related]
16. [A clinical trial to prevent the renal toxicity of cisplatin by administration of bismuth subnitrate].
Taniwaki M; Yokota S; Nishida K; Tsuda S; Edagawa J; Misawa S; Takino T; Abe T
Gan To Kagaku Ryoho; 1988 Mar; 15(3):531-3. PubMed ID: 3348637
[No Abstract] [Full Text] [Related]
17. Acute ischemic vascular events and cisplatin.
Talcott JA; Herman TS
Ann Intern Med; 1987 Jul; 107(1):121-2. PubMed ID: 3592440
[No Abstract] [Full Text] [Related]
18. Pancreatitis following cisplatin: a case report.
Bunin N; Meyer WH; Christensen M; Pratt CB
Cancer Treat Rep; 1985 Feb; 69(2):236-7. PubMed ID: 3855700
[No Abstract] [Full Text] [Related]
19. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
Mantovani G; Ghiani M; Curreli L; Maccio A; Massa D; Succu G; Lai P; Massa E; Mudu MC; Astara G
Oncol Rep; 1999; 6(2):421-6. PubMed ID: 10023014
[TBL] [Abstract][Full Text] [Related]
20. [Myocardial infarction during a treatment combining etoposide and cisplatin].
Caron F; Valy Y; Meurice JC; Perault MC; Patte F
Presse Med; 1997 Nov; 26(35):1674. PubMed ID: 9452745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
